The effect of leflunomide on cycling and activation of t-cells in HIV-1-infected participants

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Read, Sarah W ^a   Degrezia, Mary ^a   Ciccone, Emily J ^a   Dersimonian, Rebecca ^a   Higgins, Jeanette ^b   Adelsberger, Joseph W ^b   Starling, Judith M ^c   Rehm, Catherine ^a   Sereti, Irini ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; COLESTYRAMINE; HLA DR ANTIGEN; KI 67 ANTIGEN; LEFLUNOMIDE; PLACEBO; IMMUNOLOGIC FACTOR; ISOXAZOLE DERIVATIVE; VIRUS RNA;

ABDOMINAL CRAMP; ADULT; APOPTOSIS; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; IMMUNOMODULATION; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MALE; MEMORY T LYMPHOCYTE; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE CYCLING; TASTE DISORDER; XEROSTOMIA; BLOOD; CYTOLOGY; DRUG EFFECT; DRUG TOXICITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; PHENOTYPE; PHYSIOLOGY; T LYMPHOCYTE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG TOXICITY; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC FACTORS; ISOXAZOLES; LYMPHOCYTE COUNT; MALE; PHENOTYPE; RNA, VIRAL; T-LYMPHOCYTES;

EID: 77957777997     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011937     Document Type: Article

References (36)

1. Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, et al. (1998) CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol 18: 332-340.
2. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, et al. (1997) Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 16: 83-92.
3. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, et al. (2003) Persistent immune activation in HIV-1 infection is associated with progression to AIDS. Aids 17: 1881-1888.
4. Anthony KB, Yoder C, Metcalf JA, DerSimonian R, Orenstein JM, et al. (2003) Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr 33: 125-133.
5. Silvestri G, Sodora DL, Koup RA, Paiardini M, O'Neil SP, et al. (2003) Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 18: 441-452.
6. Hunt PW (2007) Role of immune activation in HIV pathogenesis. Curr HIV/AIDS Rep 4: 42-47.
7. Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, et al. (2005) Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 115: 3265-3275.
8. Sailaja G, Skountzou I, Quan FS, Compans RW, Kang SM (2007) Human immunodeficiency virus-like particles activate multiple types of immune cells. Virology 362: 331-341.
9. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365-1371.
10. Gougeon ML, Lecoeur H, Dulioust A, Enouf MG, Crouvoiser M, et al. (1996) Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol 156: 3509-3520.
11. Herbeuval JP, Hardy AW, Boasso A, Anderson SA, Dolan MJ, et al. (2005) Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells. Proc Natl Acad Sci U S A 102: 13974-13979.
12. Badley AD, Pilon AA, Landay A, Lynch DH (2000) Mechanisms of HIV-associated lymphocyte apoptosis. Blood 96: 2951-2964.
13. Wu L, Paxton WA, Kassam N, Ruffing N, Rottman JB, et al. (1997) CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 185: 1681-1691.
14. Shattock RJ, Rizzardi GP, Hayes P, Griffin GE (1996) Engagement of adhesion molecules (CD18, CD11a, CD45, CD44, and CD58) enhances human immunodeficiency virus type 1 replication in monocytic cells through a tumor necrosis factor-modulated pathway. J Infect Dis 174: 54-62.
15. Estes J, Baker JV, Brenchley JM, Khoruts A, Barthold JL, et al. (2008) Collagen deposition limits immune reconstitution in the gut. J Infect Dis 198: 456-464.
16. Schacker TW, Brenchley JM, Beilman GJ, Reilly C, Pambuccian SE, et al. (2006) Lymphatic tissue fibrosis is associated with reduced numbers of naive CD4+ T cells in human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 13: 556-560.
17. Schacker TW, Reilly C, Beilman GJ, Taylor J, Skarda D, et al. (2005) Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-associated change in peripheral CD4 cell count. Aids 19: 2169-2171.
18. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, et al. (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5: e203.
19. Biron F, Lucht F, Peyramond D, Fresard A, Vallet T, et al. (1995) Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 10: 36-40.
20. Simonelli C, Nasti G, Vaccher E, Tirelli U, Zanussi S, et al. (1996) Hydroxyurea treatment in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 13: 462-464.
21. Coull JJ, Turner D, Melby T, Betts MR, Lanier R, et al. (2001) A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr 26: 423-434.
22. Margolis DM, Kewn S, Coull JJ, Ylisastigui L, Turner D, et al. (2002) The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr 31: 45-49.
23. Lederman MM, Smeaton L, Smith KY, Rodriguez B, Pu M, et al. (2006) Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. J Infect Dis 194: 1677-1685.
24. Fox RI (1998) Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol Suppl 53: 20-26.
25. Cherwinski HM, Cohn RG, Cheung P, Webster DJ, Xu YZ, et al. (1995) The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 275: 1043-1049.
26. Quemeneur L, Gerland LM, Flacher M, Ffrench M, Revillard JP, et al. (2003) Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J Immunol 170: 4986-4995.
27. John GT, Manivannan J, Chandy S, Peter S, Fleming DH, et al. (2005) A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients. Transplant Proc 37: 4303-4305.
28. Josephson MA, Gillen D, Javaid B, Kadambi P, Meehan S, et al. (2006) Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation 81: 704-710.
29. Hossain MM, Margolis DM (2001) Inhibition of HIV replication by A77 1726, the active metabolite of leflunomide, in combination with pyrimidine nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 28: 199-201.
30. Schlapfer E, Fischer M, Ott P, Speck RF (2003) Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea. Aids 17: 1613-1620.
31. Sereti I, Herpin B, Metcalf JA, Stevens R, Baseler MW, et al. (2001) CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients. Aids 15: 1765-1775.
32. Lempicki RA, Kovacs JA, Baseler MW, Adelsberger JW, Dewar RL, et al. (2000) Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients. Proc Natl Acad Sci U S A 97: 13778-13783.
33. Yun Z, Lewensohn-Fuchs I, Ljungman P, Ringholm L, Jonsson J, et al. (2003) A real-time TaqMan PCR for routine quantitation of cytomegalovirus DNA in crude leukocyte lysates from stem cell transplant patients. J Virol Methods 110: 73-79.
34. Paiardini M, Pandrea I, Apetrei C, Silvestri G (2009) Lessons learned from the natural hosts of HIV-related viruses. Annu Rev Med 60: 485-495.
35. Chan V, Charles BG, Tett SE (2005) Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. Br J Clin Pharmacol 60: 257-264.
36. van Roon EN, Jansen TL, van de Laar MA, Janssen M, Yska JP, et al. (2005) Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64: 569-574.